JAMA & ARCHIVES
Arch Fam Med
SEARCH
GO TO ADVANCED SEARCH
HOME  PAST ISSUES  TOPIC COLLECTIONS  CME  PHYSICIAN JOBS  CONTACT US  HELP
Institution: STANFORD Univ Med Center  | My Account | E-mail Alerts | Access Rights | Sign In
  Vol. 9 No. 6, June 2000 TABLE OF CONTENTS
  Archives
  •  Online Features
  Brief Report
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (22)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Dermatology
 •Dermatologic Disorders, Other
 •Infectious Diseases
 •Bacterial Infections
 •Alert me on articles by topic

Failure of Treatment With Cephalexin for Lyme Disease

John Nowakowski, MD; Donna McKenna, ANP; Robert B. Nadelman, MD; Denise Cooper, BS; Susan Bittker, MS; Diane Holmgren, RN; Charles Pavia, PhD; Russell C. Johnson, PhD; Gary P. Wormser, MD

Arch Fam Med. 2000;9:563-567.

Context  Lyme disease typically presents with a skin lesion called erythema migrans (EM), which though often distinctive in appearance may be confused with cellulitis. The first-generation cephalosporin, cephalexin monohydrate, is effective for treating bacterial cellulitis but has not been recommended or studied for treating Lyme disease because of poor in vitro activity.

Objective  To describe the outcome of patients with EM who were treated with cephalexin.

Patients and Methods  Patients presenting with EM to the Lyme Disease Diagnostic Center in Westchester, NY (May 1992-September 1997). A 2-mm punch biopsy specimen of the leading edge of the EM lesion and/or blood was cultured for Borrelia burgdorferi.

Results  Eleven (2.8%) of 393 study patients had been initially treated with cephalexin prior to our evaluation; 9 (82%) were originally diagnosed with cellulitis. Cephalexin was administered for 8.6 days (range, 2-21 days) prior to presentation. All 11 patients had clinical evidence of disease progression, including 8 whose rash enlarged, 2 who developed seventh-nerve palsy (1 with new EM lesions), and 1 who developed new EM lesions. Borrelia burgdorferi grew in cultures from 5 patients despite a mean of 9.8 days of treatment with cephalexin (range, 5-21 days).

Conclusion  Cephalexin should not be used to treat early Lyme disease and should be prescribed with caution during the summer months for patients believed to have cellulitis in locations where Lyme disease is endemic.


From the Division of Infectious Diseases (Drs Nowakowski, Nadelman, and Wormser and Ms McKenna, Ms Cooper, Ms Bittker, and Ms Holmgren), Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla; the Department of Microbiology (Dr Johnson), University of Minnesota, Minneapolis; and New York College of Osteopathic Medicine Microbiology Laboratory (Dr Pavia), New York Institute of Technology, Old Westbury.


RELATED ARTICLE

The Archives of Family Medicine Continuing Medical Education Program
Arch Fam Med. 2000;9(6):551-552.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Clinical practice. Early Lyme disease.
Wormser
NEJM 2006;354:2794-2801.
FULL TEXT  

Diagnosis of Lyme Borreliosis
Aguero-Rosenfeld et al.
Clin. Microbiol. Rev. 2005;18:484-509.
ABSTRACT | FULL TEXT  

In Vitro Susceptibility Testing of Borrelia burgdorferi Sensu Lato Isolates Cultured from Patients with Erythema Migrans before and after Antimicrobial Chemotherapy
Hunfeld et al.
Antimicrob. Agents Chemother. 2005;49:1294-1301.
ABSTRACT | FULL TEXT  

Efficacy of Short-Course Ceftriaxone Therapy for Borrelia burgdorferi Infection in C3H Mice
Pavia et al.
Antimicrob. Agents Chemother. 2002;46:132-134.
ABSTRACT | FULL TEXT  

Lyme Disease
Steere
NEJM 2001;345:115-125.
FULL TEXT  

Efficacy of an Evernimicin (SCH27899) In Vitro and in an Animal Model of Lyme Disease
Pavia et al.
Antimicrob. Agents Chemother. 2001;45:936-937.
ABSTRACT | FULL TEXT  




HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.